Evidence map›Paper›PMID 34276222›Full record

ArticleClinical, cosmetic and investigational dermatology2021

The 10-Point Plan 2021: Updated Concepts for Improved Procedural Safety During Facial Filler Treatments.

Izolda Heydenrych, Koenraad De Boulle, Krishan Mohan Kapoor, Dario Bertossi

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. LA VISIONAesthetic plastic surgery · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Facial Overfilled Syndrome: A Narrative Clinical Review.Clinical, cosmetic and investigational dermatology · 2026
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. A Review: Causes, Consequences, and Management Strategies of Facial Overfilling.Clinical, cosmetic and investigational dermatology · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. Hyaluronic Acid Fillers and ASIA Syndrome: Case Studies.Clinical, cosmetic and investigational dermatology · 2023
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 4 countries.

Izolda HeydenrychCape Town Cosmetic Dermatology Centre, Century City, Cape Town, South Africa.ORCID 0000-0002-5660-8520
Koenraad De BoulleAalst Dermatology Clinic, Aalst, Belgium.ORCID 0000-0003-3578-0425
Krishan Mohan KapoorDepartment of Plastic Surgery, Fortis Hospital, Mohali, India.ORCID 0000-0002-3134-4266
Dario BertossiMaxillofacial Department, University of Verona, Verona, Italy.ORCID 0000-0002-8635-9967
City of Cape Town · ZAFortis Hospital · INOnze Lieve Vrouwziekenhuis Hospital · BEUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dermal filler treatments require constant reassessment for improving and safeguarding the rapidly evolving aesthetic field. Suboptimal injection technique, patient selection and product knowledge have touted a concerning increase in filler complications, with new challenges such as the COVID-19 pandemic leading to new paradigms in the understanding, prevention, diagnosis and treatment of complications. The updated 10-point plan has been developed to curtail complications through consideration of causative factors, categorized as patient, product, and procedure-related. Patient-related factors include a preprocedural consultation with careful elucidation of skin conditions (acne, rosacea, dermatitis), systemic disease (allergies, autoimmune disease, underlying bacterial and viral disease (herpes simplex virus, COVID-19 infection), medications (antineoplastic drugs, recreational drugs) and previous cosmetic procedures (including fillers and energy-based devices). Patient assessment should include standardized photography and also evaluate the role of social media, ethnicity, gender, generational, and LGBTQ+ needs. Specified informed consent for both adverse events and their treatment is essential due to the increase in vascular complications, including the risk of blindness. Product-related factors include the powerful advantage of reversibility when using hyaluronic acid (HA) products. Product characteristics such as molecular weight and filler degradation should be understood. Product layering over late or minimally degradable fillers is still inadvisable due to the initial filler being teased into reactivity. Procedural factors such as consistent photographic documentation, procedural planning, aseptic non-touch technique (ANTT), knowledge of topographical anatomy and angiosomes, and technical dexterity including pinch anatomy and needle skills are of pivotal importance. The final section is dedicated to algorithms and checklists for managing and treating complications such as allergic hypersensitivity reactions, vascular events, infection, edema and late-onset adverse events (LOAEs). The updated 10-point plan is a methodical strategy aimed at further minimising the risk of dermal filler complications.

Indexed as

assessmentcomplicationsdermal fillerspreventiontreatment

Identifiers

PMID34276222
PMCPMC8279269
OpenAlexW3182731394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.